Medical News Today -
5 Nov 2013 12:00
A phase II study is the first to show that adding two targeted therapy drugs to the standard chemotherapy regimen is safe and effective as first-line treatment of advanced non-small-cell lung cancer (NSCLC). The researchers found that the safety of the drugs compared well with the safety reported in studies of the targeted drugs used alone with chemotherapy. The drug combination was also found to be effective, with a good overall response rate, progression-free survival, and overall survival. Fo...
Share this Article